secwatch.observer — SEC 8-K summary
======================================

Issuer:     KYNTRA BIO, INC. (KYNB)
CIK:        0000921299
Form:       8-K
Filed at:   2025-09-02T23:59:59+00:00
Accession:  0000950170-25-112341
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FibroGen completes $220M sale of China ops to AstraZeneca; cash runway extended to 2028
--------------------------------------------------------------------------------

- Total consideration ~$220M ($85M enterprise value + ~$135M net cash), $60M above initial guidance.
- Repaid ~$81M term loan to Morgan Stanley Tactical Value; cash runway now extended into 2028.
- Phase 2 monotherapy trial of FG-3246 in mCRPC on track to commence in Q3 2025.
- Phase 3 protocol for roxadustat in LR-MDS anemia to be submitted in Q4 2025 after positive FDA meeting.
- FibroGen retains roxadustat rights in U.S. and all markets not licensed to Astellas (excl. China/South Korea).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921299/000095017025112341/0000950170-25-112341-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921299/000095017025112341/fgen-20250829.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-112341

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer